University of Oxford
164 articles with University of Oxford
Scientists at the University of Eastern Finland and the University of Oxford have shown that small RNA molecules occurring naturally in cells, i.e. microRNAs, are also abundant in cell nuclei.
Blue Water Vaccines, Developing Universal Flu Vaccine, Completes $7m Financing Following Successful Preclinical Study
Blue Water Vaccines, a company developing a universal flu vaccine based on technology developed at the University of Oxford, has closed a $7 million seed capital round led by CincyTech.
Scholars at the University of Oxford have announced their new project, “Citizenship in a Networked Age.” Funded by Templeton World Charity Foundation, the project will culminate in 2020 in a detailed report of the team’s findings and recommendations, which will explore how humans can uphold ideals of citizenship in an evolving technological landscape.
The University of Oxford and Harrington Discovery Institute at University Hospitals Announce New Affiliation to Advance Therapies for Rare Diseases
Joint program combines capabilities to improve treatment options globally for patients with rare diseases
1/4/2019There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
New collaboration with Coalition for Epidemic Preparedness Innovations (CEPI) and The Jenner Institute is latest example of Johnson & Johnson’s ongoing commitment to global pandemic preparedness efforts
APEIRON EXPANDS EXECUTIVE BOARD AND APPOINTS DR. ANDERSON GAWECO AS CHIEF MEDICAL AND SCIENTIFIC OFFICER (CMSO)
APEIRON Biologics AG, a biotechnology company with a broad preclinical and clinical pipeline and an approved product on the market, focusing on the discovery and development of novel cancer immunotherapies, announced today the appointment of Anderson Gaweco, M.D., Ph.D. as its Chief Medical and Scientific Officer (CMSO).
BioLineRx Initiates Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it has initiated a Phase 1/2a clinical study for AGI-134.
FORMA Therapeutics and the University of Oxford Announce Multi-Year Collaboration to Advance the Development of Deubiquitinating Enzyme (DUB) Inhibitors for the Treatment of Neurodegenerative Diseases
FORMA expands translational footprint in Neurodegeneration with ARUK Oxford Drug Discovery Institute
University of Oxford and Sound Pharma Begin Phase II Clinical Trial on Novel Treatment for Bipolar Disorder
University of Oxford and Sound Pharma, are pleased to announce the initiation of a Phase II clinical trial of SPI-1005 for the treatment of patients with bipolar disorder.
Mission Therapeutics And University of Oxford Awarded Research Grant From The Michael J. Fox Foundation
Synthego Awards Synthetic sgRNA Grant To University of Oxford For CRISPR Research Applications In The UK
MDNA Life Sciences And University of Oxford To Collaborate To Develop A Mitochondrial Biomarker Blood-Based Diagnostic For Endometriosis
Donald Trump Has More Psychopathic Traits Than Hitler. How About Hillary?, University of Oxford Study